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Phospholipase D functional 
ablation has a protective effect 
in an Alzheimer’s disease 
Caenorhabditis elegans model
Francisca Vaz Bravo1,2, Jorge Da Silva1,2, Robin Barry Chan3, Gilbert Di Paolo3,4, Andreia 
Teixeira-Castro1,2 & Tiago Gil Oliveira  1,2
Phospholipase D (PLD) is a key player in the modulation of multiple aspects of cell physiology and 
has been proposed as a therapeutic target for Alzheimer’s disease (AD). Here, we characterize a PLD 
mutant, pld-1, using the Caenorhabditis elegans animal model. We show that pld-1 animals present 
decreased phosphatidic acid levels, that PLD is the only source of total PLD activity and that pld-1 
animals are more sensitive to the acute effects of ethanol. We further show that PLD is not essential 
for survival or for the normal performance in a battery of behavioral tests. Interestingly, pld-1 animals 
present both increased size and lipid stores levels. While ablation of PLD has no important effect in 
worm behavior, its ablation in an AD-like model that overexpresses amyloid-beta (Aβ), markedly 
improves various phenotypes such as motor tasks, prevents susceptibility to a proconvulsivant drug, 
has a protective effect upon serotonin treatment and reverts the biometric changes in the Aβ animals, 
leading to the normalization of the worm body size. Overall, this work proposes the C. elegans model as 
a relevant tool to study the functions of PLD and further supports the notion that PLD has a significant 
role in neurodegeneration.
Alzheimer’s disease (AD) is the most common form of late-onset dementia. One of the main pathological hall-
marks of AD is the accumulation of amyloid-beta (Aβ) plaques in the brain, derived from the sequential cleav-
age of the amyloid precursor protein (APP) by beta and gamma secretases1. Presently, there are no effective 
therapeutical options for AD and one potential strategy being pursued is to block Aβ pathological signaling. 
Remarkably, using amyloidogenesis AD mouse models, it was shown that the genetic ablation of a myriad of 
putative Aβ signaling downstream players, such as tau2, PrP3, GIVA-phospholipase A2 (GIVA-PLA2)4 or phos-
pholipase D2 (PLD2)5 ameliorates rodent behavioral cognitive deficits, independently of APP processing or Aβ 
levels modulation.
Lipids are a major constituent of the brain and specifically signaling lipids have been shown to regulate brain 
functioning and to modulate various neurodegenerative processes6. Indeed, Aβ has been shown to activate a 
group of lipid modulating enzymes, such as PLC7, GIVA-PLA24 and PLD8. While the PLC and PLA2 pathways 
are well studied, less is known about the PLD pathway. In mammals, six members of the PLD superfamily have 
been identified9. From these, there are two canonical PLD isoenzymes, PLD1 and PLD2, which are structurally 
similar and enzymatically both convert phosphatidylcholine (PC) to phosphatidic acid (PA), but differ in their 
intracellular localization and mechanisms of regulation8,10. Interestingly, in the presence of primary alcohols, such 
as ethanol, PLD preferentially uses it as a substrate, producing a specific lipid, phosphatidylethanol (PEtOH), 
which is often used to measure PLD activity8. Even though PLD2 has been shown to be involved in Aβ signaling5, 
PLD1 has been proposed to modulate APP trafficking and processing11,12. As an approach to understand the role 
of the PLD pathway in physiology and in a pathological context, the study of PLD mutant associated phenotypes 
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in several model organisms, such as nematodes, drosophila13,14 and mice5,15, can give key insights. Importantly, 
while in mice there are two PLD isoenzymes, in drosophila and in nematodes there is only one PLD enzyme16.
The study of neurodegenerative diseases in simple organisms, such as Caenorhabditis elegans, when appropri-
ately adapted to the nematode physiology, provides a powerful tool in the identification of relevant pathological 
pathways17. For instance, the strain CL2355, which overexpresses human Aβ in neurons and presents multiple 
aberrant behaviors18–20, has been proposed to be an effective model to study Aβ pathological signaling.
Here, we studied the impact of PLD genetic ablation in C. elegans in a physiological context and upon crossing 
it with an AD-like model. We showed that PLD ablation leads to a decrease in PA levels and that PLD is the only 
source of PEtOH upon ethanol treatment. While we found no major behavioral deficits, we observed a small 
increase in the worm volume. Remarkably, PLD ablation restored not only worm volume in an AD-like model, 
but also had a protective effect in motor behaviors and in sensitivity to serotonin and pharmacologically-induced 
seizures, suggesting a disease-modifying role for PLD in C. elegans.
Results
pld-1 worms present decreased PA levels and PLD activity. In order to address the role of PLD in 
C. elegans lipid metabolism (Supplementary Fig. S1), we performed a lipidomic analysis to biochemically char-
acterize the pld-1 C. elegans model. Since PLD converts PC to PA, we measured the levels of PA in N2 and pld-1 
worms, using liquid chromatography-mass spectrometry (LC-MS). We found that PLD mutants present a ~50% 
decrease in total PA levels (Fig. 1A). Specifically, six molecular species of PA (based on their different fatty acyl 
composition), namely PA 32:1, PA 34:1, PA 36:1, PA 38:1, PA 38:4 and PA 40:6 were diminished, while a trend 
for a decrease was observed for the other species (Fig. 1B). Since PLD is not the only source of PA, we developed 
an in vivo PLD activity assay, relying on the incubation of worms for 1 hour with 1% ethanol and subsequent 
measurement of phosphatidylethanol (PEtOH), a lipid uniquely produced by PLD. We found a major decrease in 
multiple PEtOH species in pld-1 comparing with N2 worms (Fig. 1D), which indicates that PLD is the only source 
of PEtOH in C. elegans. Next, we performed an ethanol susceptibility assay, since PLD uses ethanol as a substrate 
to produce PEtOH. Animals were exposed to different doses of ethanol and their mean speed was evaluated. An 
aldehyde dehydrogenase mutant (alh-6) was used as an ethanol-sensitive control strain and we observed that in 
two doses (100 and 200 mM), pld-1 worms were more susceptible than N2 animals to the acute ethanol effects, 
similarly to alh-6 animals (Fig. 1F). Moreover, in order to test if the fraction of ethanol metabolized by PLD would 
be significant in the context of total levels of ethanol, we compared total ethanol levels in N2 animals and with 
pld-1 animals after one hour of treatment and we observed no significant differences (1.00 ± 0.10 and 0.98 ± 0.08, 
in N2 vs. pld-1, resp. as relative levels to control, from three independent experiments n = 250 animals per experi-
ment). Taken together, these results show that PLD ablation in worms leads to decreased PA levels, decreased total 
PLD activity and impacts the sensitivity to ethanol acute effects.
PLD ablation causes no gross phenotypes in C. elegans. In order to perform a characterization of 
pld-1 animals, we ran a battery of tests. We first found that the number of progeny (Fig. 2A) and subsequent devel-
opment (Fig. 2B), assessed by the percentage of adult worms in the total population, was unchanged. Additionally, 
motor behavior, which was evaluated by assessing locomotion defects, was not affected in pld-1 worms (Fig. 2C). 
Considering that C. elegans has different types of sensory neurons, we performed chemotaxis assays to evaluate 
the ability of pld-1 worms to approach or avoid a compound, and we observed no differences in the chemotactic 
responses for all tested chemicals (Fig. 2D and E). Moreover, we performed an associative learning task and no 
deficits were observed in pld-1 worms (Fig. 2F). In order to evaluate the effect of PLD ablation on survival, we 
performed a lifespan assay. No differences were observed in the median lifespan of pld-1 worms when compared 
to N2 (Fig. 2G) (Supplementary Table S2). Furthermore, in order to explore the role of PLD in PA-mediated cell 
signaling, we performed a dopamine susceptibility assay. Dopamine binds to dopaminergic receptors coupled to 
a G-protein, activating several effectors, including PLC. The activation of PLC leads to an increase in diacylglyc-
erol (DAG) that could then be converted to PA. As previously described, DAG kinase 1 mutant worms (dgk-1) 
were shown to be resistant to dopamine21. However, even though DGK and PLD are both sources of PA, pld-1 
animals presented no differences in the susceptibility to dopamine induced locomotion impairment (Fig. 2H). 
Thus, our observations suggest that PLD ablation has no impact in worm lifespan and causes no gross behavioral 
alterations.
PLD modulates the body size of C. elegans. As part of our characterization of PLD mutants, we per-
formed a biometric analysis and interestingly we observed that pld-1 animals consistently presented an increase 
(~10%) volume of the body when compared to N2 worms (Fig. 3A and B). Importantly, we saw no differences 
in the defecation cycles (Fig. 3C) and the pharyngeal pumping rates (Fig. 3D) of well-fed mutants. Using Nile 
red fluorescence, an indicator of neutral lipid content, we showed that pld-1 animals presented an increase 
(~30%) in lipid accumulation (Fig. 3E and F). It was previously shown that cholesterol deprivation leads to 
developmentally-induced volume reduction in the F2 generation22,23. We evaluated the impact of PLD ablation in 
this lipid induced developmental volume deficit and we observed that pld-1 animals had no volume differences 
compared to N2 in cholesterol-deprived F2 generation animals (Fig. 3G). These results suggest that PLD regulates 
worm body size and lipid stores.
PLD functional ablation ameliorates Aβ phenotypes in an AD-like model. We had previously 
observed that the CL2355 strain (Aβ), which has a pan-neuronal expression of Aβ after induction by tempera-
ture up-shift to 23 °C, presented a major decrease (~40%) in worm volume (Fig. 4A). We then crossed the pld-1 
strain with the Aβ strain to test the impact of PLD functional ablation in an AD-like model. Remarkably, pld-1; 
Aβ animals presented significantly higher volumes than Aβ worms (Fig. 4B). Taking into account our previous 
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Figure 1. pld-1 animals show decreased PA levels and PLD activity. (A) pld-1 ablation causes a 50% 
reduction on total phosphatidic acid (PA) relative levels in C. elegans. (B) Relative amounts of the different PA 
species measured in pld-1 and WT animals. Levels of PA were quantified by Liquid Chromatography Mass 
Spectrometry (LC-MS) analysis (n = 6). (C) Relative amounts of total PEtOH (D) and of the different PEtOH 
species measured in pld-1 and WT animals (n = 6) and quantified by LC-MS. (E) Graphical representation 
of the synthesis reaction of phosphatidylethanol (PEtOH) in vivo. PLD has an increased affinity to primary 
alcohols, leading to the generation of PA in the presence of water, or PEtOH if in the presence of ethanol. This 
reaction is the only source of PEtOH and can be used as a measure of PLD activity. (F) pld-1 animals are more 
susceptible than WT to the acute effects of ethanol (at 100 and 200 mM), similarly to the ethanol-susceptible 
strain alh-6, as shown by the decrease in the mean speed of the animals (n = 6). Values denote mean ± SEM 
(*p < 0.05, ***p < 0.001). The nomenclature for PA and PEtOH fatty acid species composition is expressed as 
total chain length: number of unsaturated bonds.
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Figure 2. pld-1 animals show no major phenotypic alterations. (A–C) Effect of PLD ablation on C. elegans 
egg-laying, development and locomotion behavior. (A) Number of progeny of adult hermaphrodite N2 
and pld-1 animals for 5 h. The progeny of 10 worms was counted per experiment (n = 3). (B) Percentage of 
L4 to adult N2 and pld-1 animals after 48 h post egg laying. At least 150 animals were averaged per dataset 
(n = 3). (C) The percentage of locomotion defective age-synchronized adult animals (day 3 post-hatching) 
was measured by scoring the animals that remain inside a 10 mm circle, 1 min after being placed on its center. 
The number of animals used per trial was 10 (n = 3). (D,E) pld-1 worms have a normal chemotaxis response. 
Chemotaxis response to NaCl and isoamyl alcohol (IAA) was evaluated in N2, pld-1, che-1 and osm-6 animals. 
Mutant strains unable to detect NaCl (osm-6 and che-1) and IAA (osm-6) were used as negative controls. Three 
independent experiments were performed (n = 200 worms per assay). (F) pld-1 animals have no deficit in an 
associative learning task. N2 and pld-1 short-term and long-term associative memory profile after 1 h and 24 h 
of conditioning. Representative example of three independent experiments is shown (n = approximately 100 
worms per chemotaxis assay plate). (G) pld-1 worms have a normal lifespan. Kaplan-Meier survival curve of 
pld-1 worms, show no difference in the median lifespan. Survival rate was scored everyday and is expressed as 
percentage of survival. daf-2 and daf-16 strains were used as long and short-lived controls, respectively. The 
data results from the analysis of 100 worms per strain in 3 independent experiments. (H) Dose-response curves 
measuring paralysis induced by exogenous dopamine. Locomotion impairment of animals moving 30 min 
after being placed on agar plates containing the indicated concentrations of dopamine is shown. N2 and pld-1 
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work showing that Pld2 genetic ablation had a protective effect in synaptic and behavioral deficits in an AD 
amyloidogenesis mouse model5, we tested if the functional ablation of PLD in worms had not only an effect in 
the volume of Aβ worms but also in other phenotypes. First, we performed a lifespan assay, conducted at 23 °C, 
in order to evaluate the effect of neuronal Aβ expression on overall survival. We observed a significant decrease 
in the median life span of Aβ worms compared to N2 and interestingly pld-1; Aβ animals presented increased 
median survival relative to Aβ worms (Fig. 4C) (Supplementary Table S3). Moreover, while we observed dimin-
ished egg-laying in Aβ animals (Fig. 4D), the ablation of PLD in the Aβ background resulted in an increase in the 
number of laid eggs (Fig. 4D) (Supplementary Fig. S3). Egg viability was not affected by either Aβ or PLD ablation 
(Fig. 4E). Concerning motor task assessment, both crawling and swimming were shown to be impaired in Aβ 
worms and, again, PLD ablation partially restored these deficits in pld-1; Aβ worms (Fig. 4F and G). We also eval-
uated the sensitivity of animals to serotonin, since it was previously shown that Aβ transgenic worms are more 
sensitive to this neurotransmitter18. Notably, pld-1; Aβ worms presented reduced sensitivity to serotonin-induced 
impairments when comparing with Aβ worms (Fig. 4H). Finally, we performed a pharmacologically-induced 
pro-excitatory assay using pentylenetetrazol (PTZ), a GABA receptor antagonist that increases neuronal excit-
ability by disrupting the normal excitatory/inhibitory balance24. We exposed worms to different doses of PTZ 
and measured seizure severity. We showed that while Aβ transgenic worms have increased susceptibility to the 
effects of PTZ, PLD functional ablation confers a protective effect in PTZ-susceptibility induced by Aβ expression 
(Fig. 4I) (Supplementary Table S5). Taken together, these observations indicate that PLD ablation protects from 
Aβ-induced deficits.
Discussion
PLD is a lipid modulatory enzyme involved in multiple aspects of cell physiology, such as signaling and mem-
brane trafficking processes. Furthermore, it has been implicated in pathologic conditions like cancer and neu-
rodegenerative diseases8,25. To understand the role of PLD, mutant models have been developed using different 
organisms, such as mice5,15 and flies13,14. While in mammals there are two canonical isoenzymes, PLD1 and PLD2, 
in flies and nematodes there is only one PLD ortholog16.
Here, we present an extensive characterization of the effects of PLD ablation using a C. elegans model. We 
show that PLD mutants, pld-1, have decreased levels of PA (Fig. 1A) and that PLD is the only source of PEtOH 
(a specific product of PLD activity) (Fig. 1C). This is in accordance with the results from another model organ-
ism, showing that with the genetic ablation of PLD in drosophila, PLD was the only source of PLD activity13. In 
mammals, the contribution to total PLD activity by either PLD1 or PLD2 depends on the tissue or cell type. For 
instance, it was previously shown in the brain that while PLD2 ablation leads to decreased total PLD activity5, no 
changes are observed in total PA levels5,26. In another study, it was observed that PLD1 ablation led to decreased 
PLD activity in the liver and while there were no differences in total PA levels, PA supplementation restored auto-
phagy deficits in PLD1 knock-out cells27. Moreover, we show that PLD metabolizes ethanol, producing PEtOH, 
and that pld-1 animals are more sensitive to ethanol-induced slowing (Fig. 1F). While PEtOH measurements 
provide direct evidence that PLD metabolizes ethanol acutely, we observed no differences in total ethanol levels 
after one hour treatment, suggesting, at least in C. elegans, PLD has a minor role for ethanol elimination. The 
increased sensitivity of pld-1 animals to acute ethanol effects could be explained alternatively by a diversion of 
PA synthesis or due to potential protective effects by PEtOH. Accordingly, previous reports showed that, not only 
chronic ethanol exposure, with associated production of PEtOH28,29, but also PEtOH itself30, induce resistance 
to acute ethanol effects on membranes, which suggests that PEtOH could have a protective role in acute ethanol 
exposure. Since in mammals there are two PLDs, the specific role of either PLD1 or PLD2 in ethanol-induced 
toxicity should be differentially studied.
Our results show that PLD is not essential for the survival or for the normal functioning of various behavioral 
tasks in a C. elegans model (Fig. 2). In mice, both PLD1 and PLD2 knock-out animals are viable5,15. Even though 
it was reported that PLD1 or PLD2 ablation led to decreased juvenile brain volume and to social and object rec-
ognition deficits31, no major behavioral deficits were observed by other research groups in PLD2 knock-out adult 
mice8,26, apart from olfaction deficits in aged animals26.
Concerning biometric and metabolic parameters, deletion of either of the PLD enzymes led to elevated body 
weight and increased adipose tissue content in aged animals32. However, while others did not observe elevated 
body weight in PLD2 knock-out animals33, PLD1 knock-out animals presented not only increased hepatic weight, 
but also increased triacylglycerol levels and increased cholesterol levels27. Here, in a C. elegans model, we observe 
that pld-1 animals present both increased size and lipid stores (Fig. 3). We show that PLD is a main source of PA 
in C. elegans (Fig. 1A), so it is possible that the effects of PLD perturbation could be due to altered PA metabolism. 
Therefore, other enzymes, which modulate PA levels, such as lipin (i.e., a phosphatic acid phosphatase), could 
potentially be involved in the regulation of convergent physiologic mechanisms. Curiously, it was previously 
shown that silencing of the C. elegans homolog of lipin (lpin-1) leads to reduced body size and defects in lipid 
storage34. It was also observed in C. elegans that depletion of PC synthesis enzymes stimulates sterol regulatory 
element binding protein (SREBP) transcription factors, increases both fat-7 levels and lipid stores35 and in a 
follow-up study lpin-1/Lipin-1 knock-down reduced the effects of PC-depleted conditions in a PA dependent 
way36. Since lipin-1 converts PA to DAG, our data raises the possibility that in C. elegans, the PA species derived 
animals show no differences to N2 in sensitivity to dopamine, whereas dgk-1 animals exhibit resistance to 
paralysis induced by exogenous dopamine. The data for three independent experiments is represented (n = 10 
animals for each dopamine concentration). Values denote means ± SEM, ns-non-significant. (**p ≤ 0.01, 
***p ≤ 0.001).
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from PLD, could be involved in the mechanism of lipid stores regulation observed upon lpin-1 knock-down. 
Moreover, lipid stores have been previously shown to be consumed through a specialized form of macroauto-
phagy called macrolipophagy37. Since, previous reports have shown a role for PLD1 in macroautophagy38 and 
in the regulation of lipid stores27 we hypothesize that this could be an alternate explanation for this phenotype.
To understand the impact of PLD ablation in a neurodegenerative disease C. elegans model, we crossed pld-1 
animals with the CL2355 strain, which overexpresses human Aβ in neurons. This Aβ strain was shown to present 
multiple behavioral deficits and decreased survival18–20. We had previously observed that C. elegans expressing Aβ 
presented decreased worm size, and remarkably, pld-1; Aβ animals had a significant recovery in animal volume 
(Fig. 4B), with a major impact in worm survival (Fig. 4C). Additionally, PLD ablation in pld-1; Aβ animals had 
a protective effect in motor behaviors (Fig. 4F and G) and in the defective responses to serotonin (Fig. 4H) and 
PTZ (Fig. 4I). This is in line with previous results showing that Aβ leads to increased total PLD activity and that 
PLD2 genetic ablation ameliorates synaptic and behavioral deficits in an amyloidogenesis AD mouse model, inde-
pendently of an effect on APP processing5. Interestingly, in an unbiased gene expression study, it was observed 
in another C. elegans strain expressing human Aβ that the toxic peptide leads to gene expression changes that 
overlap with changes induced by the membrane pore-inducing toxin, Cry5B39, suggesting that membrane damage 
mechanisms could be important pathways induced by Aβ. In fact, PLD has been shown to be involved in mem-
brane damage pathways40. Moreover, fly PLD was shown to be required to support rhabdomere volume during 
illumination, a task that relies on active membrane turnover13. Previously it had been shown that PLD overexpres-
sion also has a deleterious impact, leading to degeneration of rhabdomeres14,16. These reports in drosophila, show 
that either a decrease or increase in PLD levels can have a functional impact in fly rhabdomeres, which highlights 
the importance of tightly regulating PLD activity in physiologic processes with high membrane turnover.
To our knowledge, this is the first report evaluating the impact of PLD ablation in C. elegans. We further pres-
ent observations that support PLD as a downstream pathway of Aβ’s interaction with membranes or a putative 
membrane receptor. Overall, we observe multiple phenotypes that somewhat phenocopy previous observations 
in other PLD genetic models. Future studies will be able to benefit from C. elegans PLD models as relevant tools 
to study the role of PLD in physiologic and pathologic mechanisms.
Figure 3. PLD modulates C. elegans volume. (A,B) pld-1 worms have an increase in body volume. Representative 
photos (A) and graphic analysis of volume (B) of N2 and pld-1 animals at day 3 after egg laying. The scale bar 
represents 100 µm. (B) 40 animals were analyzed per strain in 3 independent experiments. (C,D) pld-1 worms have 
no alterations in physiological parameters, namely (C) defecation cycle length and (D) pharyngeal pumping rate 
(n = 3, 10 animals per assay). (E,F) pld-1 worms have changes in lipid balance. Nile Red staining representative 
photos (E) and quantification of Nile Red fluorescence of N2 and pld-1 worms at day three post-hatching. 
Photographs were taken at 60 × magnification. Scale bar represents 100 µm. (G) pld-1 and N2 animals present 
similar volumes upon cholesterol depletion. Volume analysis of F2 generation (N2 and pld-1) animals at 72 h after 
egg laying, in the presence or absence of cholesterol. The data results from the analysis of 45 worms per strain in 4 
independent experiments. Values denote means ± SEM. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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Figure 4. PLD functional ablation ameliorates Aβ induced phenotypes. (A) Representative photos of Aβ and 
pld-1;Aβ and volume (B) of N2, pld-1, Aβ and pld-1;Aβ animals at day 3 after egg laying. The scale bar represents 
100 µm. (B) Aβ transgenic worms have a decrease in body size, which is partially renormalized upon PLD 
ablation. The data results from the analysis of 45 worms per strain in 4 independent experiments. Values denote 
means ± SEM. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). (C) Effects of neuronal Aβ expression on adult lifespan at 
23 °C. The experiment was conducted twice with 100 worms per strain. Representative example of two independent 
experiments is shown. Kaplan-Meier survival curve of Aβ and pld-1; Aβ worms, showing differences in the median 
lifespan compared with N2 and pld-1 animals. The mean adult lifespan of pld-1; Aβ animals was significantly 
longer than Aβ transgenic animals. (D–I) Neuronal expression of Aβ in C. elegans leads to a defect in brood 
size(D), locomotion (F), decrease in thrashes over time (G), serotonin sensitivity (H) and pentylenetetrazol (PTZ) 
susceptibility (I), when compared to the N2 and pld-1 animals. (D) Improvement in brood size due to ablation 
of PLD in Aβ animals. Total number of progeny of adult hermaphrodite N2, pld-1, Aβ and pld-1; Aβ worms for 8 
days. The progeny of 15 worms was counted per experiment (n = 2). (E) Egg viability was not significantly affected 
by neuronal expression of Aβ (n = 3). (F) Aβ worms have a motility defect partially recovered by PLD ablation. 
Percentage of uncoordinated N2, pld-1, Aβ and pld-1; Aβ adult hermaphrodite animals was measured by scoring 
the animals that remain inside 10 mm circle after 1 min (n = 4 experiments, 10 worms per strain and experiment). 
(G) The number of body thrashes per 30 seconds was partially rescued by PLD ablation in Aβ transgenic animals 
(n = 4 experiments, 10 worms per strain and experiment). (H) PLD ablation in Aβ animals leads to a decrease in 
hypersensitivity to 1 mM serotonin caused by Aβ (n = 4 experiments, 60 worms per strain and experiment). (I) PLD 
ablation reduces seizure-severity induced by PTZ in Aβ transgenic worms. PTZ susceptibility of worms were scored 
after exposure to the concentrations of 20, 40, 50, 80 and 100 mg/mL of PTZ (n = 4 experiments, 15 animals per 
dose/strain/experiment). Values denote means ± SEM. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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Methods
Nematode Strains and culture conditions. Strains used in this work were acquired from the Caenorhabditis 
Genetics Center, namely Bristol N2; RB1737, pld-1(ok2222) II; CB1370, daf-2(e1370) III; CF1038, daf-16(mu86) I; 
PS2627, dgk-1 (sy428) X; PR811, osm-6 (p811) V; PR696, che-1 (p696) I, and CL2355, smg-1(cc546) dvIs50 I, dvIs50 
[pCL45 (snb-1: Abeta 1–42::3’ UTR(long) + mtl-2::GFP]. The CL2355 strain has a pan-neuronal expression of Aβ1–
42, which is inducible by temperature up-shift to 23 °C. The transgenic strain is referred to as neuronal Aβ strain. All 
the strains were backcrossed to Bristol strain N2 eight times. Strain CL2355 was crossed with strain RB1737 using 
standard procedures, generating pld-1; Aβ animals. Worms were grown in agar plates with nematode growth media 
(NGM) at 20 °C as previously described41. In the experiments where the Aβ strain was used, the animals grew 36 h at 
16 °C followed by temperature upshift to 23 °C. Synchronized cultures were used for all assays and obtained through 
egg laying, by collecting embryos laid by adult animals during 3 h or using a bleaching procedure, by treating animals 
with an alkaline hypochlorite solution (0.5 M NaOH, 2.6% NaClO) for 7 min42.
Lipid analysis. N2 and pld-1 animals were incubated in the presence or absence of ethanol (1%) for 1 h and 
all samples were immediately collected, frozen in liquid nitrogen and stored at −80 °C until further processing. 
Approximately 100 animals were used per sample. Lipids were subsequently extracted by a chloroform/methanol 
extraction, as previously described43,44. Lipid species were analyzed using a 6490 Triple Quadrupole LC/MS sys-
tem (Agilent Technologies, Santa Clara, CA) operated in multiple reactions mode (MRM). PA and PEtOH levels 
were quantified by comparing to spiked internal standards diC17-PA and diC16-PEtOH (Avanti Polar Lipids). 
Lipid concentration was normalized by molar concentration across all species for each sample, and the final data 
is presented as the mean mol %43,44.
Ethanol susceptibility assay. Plates (60 mm) with 8,5 mL NGM and 1 mL of ethanol at final concentra-
tions ranging from 100 to 500 mM (adjusted to the volume of the agar) were freshly prepared. Plates were then 
sealed for 2 h at room temperature (RT) and copper rings (10 mm diameter) were melted onto the agar surface. 
Day three synchronized worms were placed in plates in the absence of food for 30 min prior to the assay, and then 
transferred to the ethanol plates. After 20 min of exposure, one-min videos were taken with an Olympus PD72 
digital camera attached to an Olympus SZX16 stereomicroscope. Mean worm speed was quantified using the 
dVision software (Delta Informatika ZRt, Budapest, Hungary)45.
Ethanol Assay Kit. Worms were synchronized by egg laying and grown at 20 °C until they reached the adult 
stage (day three post-hatching). Ethanol levels were assayed using the ethanol assay kit (MAK076, Sigma). Briefly, 
nematodes were washed in M9 buffer and 50 worms were placed per well to a final volume of 50 µL with the etha-
nol assay buffer. The master reaction mix was prepared according to the specifications of kit. To each well, 50 µL of 
the master reaction mix were added, and incubated for 60 min at room temperature, after which the absorbance 
at 570 nm (A570) was measured. The concentration of ethanol was determined based on the A570 of standards 
provided in the kit.
Fecundity and Egg Viability Assay. Animals were synchronized by egg-laying. At day three, animals were 
individually transferred into 30 mm plates (10 animals per strain) with a bacterial lawn of 10 mm of diameter. 
After 5 h, all worms were removed and the total number of eggs in each plate was counted. The plates were main-
tained at 4 °C in order to delay egg hatching, while counting them. Egg viability was determined as the percentage 
of eggs that were able to hatch over the following 24 h.
Brood Size. Brood size evaluation was performed as previously described46. Briefly, 15 L4 animals, per strain, 
were kept at 23 °C in individual plates (30 mm) with a bacterial lawn of 10 mm of diameter and allowed to lay eggs. 
Animals were transferred to fresh plates daily and total progeny counted every day for 8 days.
Development. Synchronized worms through hypochlorite treatment were placed in a freshly seeded NGM 
plate (50 animals per strain). After 48 h, the percentage of animals which were in the L4 to adult stage was scored.
Motility assay. The motility assay was performed as previously described47 at RT (~20 °C), using day 
three synchronized animals grown at 20 °C. Five animals were placed simultaneously in the middle of a 
freshly seeded plate, equilibrated at 20 °C. Animals remaining inside a 10 mm circle after 1 min were scored as 
locomotion-defective. At least 150 animals were scored for each strain in three independent assays.
Chemotaxis assay. Chemotaxis assays were performed based on the assays previously developed48,49. 
Well-fed, synchronized adult day three animals (through bleaching) were collected and washed with S-Basal 
buffer three times to remove all the food. The assay plates (20 g/L agar-agar; 5 mM KH2PO4; 1 mM CaCl2; 1 mM 
MgSO4) were prepared by adding 1 µL of 5 M NaCl or 0.1 M isoamyl alcohol (IAA) 10 mm from the center of 
the plate on one side. On the opposite side of the plate, a 1 µL drop of water or of 100% ethanol was added. 
Afterwards, 1 µL of 1 M sodium azide was additionally added to the preexisting spots to paralyze the animals. 
Worms (~100–200) were quickly transferred to the center of the plate and the excess of liquid removed with a 
filter paper. The assay plates were incubated at 20 °C for 60 min and the chemotaxis index was scored as the (num-
ber of animals at attractant - number of animals at counter-attractant)/Total number of animals in assay. Three 
to four independent assays were conducted with at 100 to 150 animals per assay per plate. For each strain, two to 
three plates were tested per assay.
Short-term and Long-term Associative Memory Assays. A C. elegans odorant preference assay proto-
col was adapted from previous reports50. A chemotaxis assay using 1 M diacetyl (Sigma-Aldrich) was performed 
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as described above in order to confirm that the animals’ genotype did not affect the chemotaxis index to diacetyl 
(naive group). To assess the 1× associative learning, well-fed day three animals were starved for 1 h in the presence of 
diacetyl and placed on the lid of the plates. Right after the starvation period, the chemotaxis index was scored again 
to assess learning (represented as starv 1 h in the graph). After conditioning the worms with diacetyl, worms were 
placed on NGM plates with food for 1 h. To test for short-term associative memory of the food-diacetyl association, 
the chemotaxis index was again evaluated (short memory). The long term associative memory was performed 24 h 
later (long memory). As a control, the same conditions were tested in fed animals to test for habituation.
Lifespan. Synchronized adult animals were placed on 60 mm NGM plates at 20 °C, examined every day and 
scored as dead if no mechanical response was obtained after gentle touch with a platinum wire. Animals were 
transferred to fresh plates every 2 days to avoid starvation and progeny contamination. Animals were censored 
from the analysis if lost, desiccated on the edge of plates, if showing extruded gonad or suffered internal progeny 
hatching. Evaluations ended after all animals were dead or censored. The lifespan evaluation at 23 °C was per-
formed as described above. Experiments were performed blindly.
Dopamine susceptibility assay. Worms were synchronized by egg laying and grown at 20 °C until they 
reached the adult stage (day three post-hatching). Different solutions of dopamine hydrochloride (Sigma-Aldrich) 
(concentrations ranging from 100 to 800 mM) were prepared and 1 mL of the solution was added to NGM plates 
(60 mm) without OP50 and allowed to dry for 60 min. The adult worms were placed in each plate (10 animals 
per strain) and after 30 min their motor phenotype was assessed according to the following scores: 0 for normal 
locomotion, 1 for sluggish/slower movement, 2 for semi-paralysis (body bends without moving), 3 for paralysis 
(only the head moves after mechanical stimulation) and 4 for death21.
Biometric analysis. Biometric analysis was performed at 72 h after egg laying. Length and diameter meas-
urements were calculated using ImageJ software®, and volume was determined by treating worms as cylinders 
(v = π*r2*l)51.Biometric analysis of F2 animals was performed using the progeny of synchronized worms grown 
in NGM plates with or without cholesterol. Pictures were acquired 72 h after hatching. Worms were photographed 
using an Olympus PD72 digital camera attached to an Olympus SZX16 stereomicroscope.
Nile Red Staining. The Nile red staining protocol was adapted from previously described protocols52. Nile 
red (Molecular Probes) was dissolved in a 0.5 mg/mL acetone stock solution. On the day of the assay, the stock 
solution was freshly diluted in 1× PBS to a final concentration of 1 µg/mL. Egg laying synchronized worms were 
washed 3 times with M9 and transferred to a conical tube containing Nile Red. Worms were incubated at 20 °C for 
2 h and washed 3 times to remove the excess of dye before imaging52.
Confocal Imaging. For confocal dynamic imaging and quantification of Nile Red staining, live animals were 
paralyzed with 3 mM levamisole (Sigma-Aldrich) and mounted on a 3% agarose pad. All images were acquired 
on an Olympus FV1000 (Japan) confocal microscope, under a 60× oil objective and resolution of 640 × 640. A 
z-series image was acquired for all treated worms using a 594 nm laser. The pinhole was adjusted to 1.0 Airy unit. 
The images were analyzed and processed using ImageJ software®.
Thrashing analysis. Single synchronized adult animals were transferred to a 10 µL drop of M9 buffer. After 
1 min animals were filmed at a rate of 15 frames-per-second, in a total of 600 frames, using an Olympus PD72 
digital camera attached to an Olympus SZX16 stereomicroscope. The number of total body bends per 30 seconds 
was then quantified using ImageJ software® with the wrMTrck plugin53.
Defecation Motor Program (DMP). Adult well-fed synchronized worms (10 per strain) were placed on 
NGM plates (90 mm), freshly seeded with OP50, for 10 min. Each animal was individually evaluated for exactly 
10 min and the total number of DPMs was counted in this interval. The results were expressed as the average time 
(in seconds) between each successive cycle.
Pharyngeal Pumping. Synchronized day three worms were placed on plates (90 mm) freshly seeded with 
OP50. After 1 h, worms present in the border of the OP50 were selected and recorded with an Olympus PD72 
digital camera attached to an Olympus SZX16 stereomicroscope (10 worms per strain). Each movie was recorded 
for 30s and the total number of pharyngeal contractions was counted in this interval.
Serotonin Sensitivity Assay. The serotonin assay was performed as previously described18. Serotonin (cre-
atine sulfate salt, Sigma-Aldrich) was dissolved in M9 buffer to 1 mM. Synchronized three-day worms underwent 
temperature upshift to 23 °C to activate transgene expression of the Aβ strain, prior to the assay. Worms were 
washed with M9 buffer and placed in 200 µL of serotonin 1 mM in a 96-well plate. The animals were scored as 
active or paralyzed in each well after 5 min.
PTZ susceptibility Assay. The PTZ susceptibility assay was adapted from others24. Plates (30 mm) were 
prepared with 3 mL NGM each (without food). A stock solution of 100 mg/mL PTZ (Sigma-Aldrich) and the 
respective dilutions (20, 40, 50, and 80 mg/mL) were prepared. To each plate, 250 µL of PTZ was added. The plates 
were allowed to dry for 90 min in a flow chamber. Afterwards, 5 times concentrated OP50 was added to the center 
of each plate. The susceptibility assay was evaluated by placing worms in the bacterial lawn in each plate. After 
30 min, each worm’s phenotype was evaluated using the following score: 0 for no major decrease in worm move-
ment, 1 for sluggish/slower movement, 2 for semi-paralysis (body bends without moving), 3 for paralysis (only 
the head moves after mechanical stimulation) and 4 for death.
www.nature.com/scientificreports/
1 0SCIentIfIC REPORTS |  (2018) 8:3540  | DOI:10.1038/s41598-018-21918-5
Statistical analysis. A confidence interval of 95% was assumed for all statistical tests. Normality was tested 
using the Kolmogorov-Smirnov test, and was assumed for all tested variables. In all experiments comparing two 
variables, the data was analyzed with Student’s t-test with the Levene’s test for equality of variances. When more 
than two variables were analyzed, a one-way analysis of variance with the Levene’s test for equality of variances 
and a post-hoc Tukey test for multiple comparisons was performed. The ethanol and dopamine susceptibility 
assays were analyzed using a two-way analysis of variance with the Levene’s test for equality of variances and a 
post-hoc Tukey test for multiple comparisons. The PTZ susceptibility assay was analyzed using a repeated meas-
ures analysis of variance with the Mauchly’s test for sphericity and a post-hoc Games-Howell test for multiple 
comparisons. Lifespan was evaluated by the log-rank (Mantel-Cox) test and the Hazard Ratio obtained from a 
Cox regression model, using the strain as a categorical covariate and a simple contrasts analysis. Statistical analy-
sis was performed using GraphPad Prism 6.01 software® and SPSS 22.0 (SPSS Inc.)
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